GlobeNewswire by notified

MC2 Therapeutics Receives Positive Feedback from FDA pre-IND Meeting and Updates on Indication Expansion Strategy

Share

To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

MC2 Therapeutics Receives Positive Feedback from FDA pre-IND Meeting and Updates on Indication Expansion Strategy

  • On track to file IND in mid-2025 for a Phase 2b clinical trial in Hidradenitis Suppurativa (“HS”) with MC2-32, a first-in-class, oral drug candidate targeting pathways involved in numerous Immunology and Inflammation indications (“I&I")

  • Comprehensive pre-clinical studies show that MC2-32 is highly relevant for neutrophilic dermatoses as well as other I&I diseases outside of the skin (I&I pipeline in a product)

  • MC2 Therapeutics expects to start a Phase 2 trial in rare disease Pyoderma Gangrenosum in 2025

Copenhagen, May 13th, 2024 - MC2 Therapeutics (“the Company”), a commercial stage biotech company focused on developing novel treatment paradigms for immunology and inflammatory diseases, today confirms it has received positive feedback from a pre-Investigational New Drug ("IND”) meeting with the US Food and Drug Administration (“FDA”) with respect to its first-in-class, oral drug candidate MC2-32 for the treatment of Hidradenitis Suppurativa (“HS”).

MC2-32 is a first-in-class, oral HSP90 inhibitor with a unique and highly specific pharmacological profile that elicits a full spectrum effect of HSP90 inhibition, without the class side effects. Alongside its pro-inflammatory action, MC2-32 has a specific targeted tissue distribution, supporting good clinical response profile and tolerability, as demonstrated in a Phase 2a trial published in JAMA Dermatology in December 2023. Based on initial positive feedback from the FDA and subject to the completion of already initiated pre-clinical studies, MC2 Therapeutics expects to file an IND for MC2-32 in HS in mid-2025.

MC2-32’s unique mode of action positions it well to address a multitude of other neutrophilic dermatoses as well as other I&I diseases. Consequently, MC2 Therapeutics is planning to explore MC2-32 in a Phase 2 trial in Pyoderma Gangrenosum (“PG”), a rare skin condition causing painful ulcers, for which there is a significant unmet patient need and no approved treatments. It is estimated that >50,000 people suffer from PG in the US and Europe alone, representing a very large commercial opportunity.

The potential of MC2-32 will also be investigated in additional diseases in the skin and other organs.

Jesper J. Lange, CEO of MC2 Therapeutics, commented: “Encouraging feedback from the FDA marks an important milestone in the continued clinical development progress of our oral drug candidate MC2-32 and is a testament to the high quality of work by our team. Proceeding to the initiation of our Phase 2b trial for HS will be the first step to exploit the full potential of MC2-32 in several I&I indications where patients are currently left with no or limited treatment options. We look forward to working closely with the FDA, our investigators and stakeholders to advance the next phase of development.”

Prof. Lars Iversen, CMO of MC2 Therapeutics, commented: “MC2-32’s novel mode of action, targeting multiple pro-inflammatory pathways and with specific tissue targeting properties, highlights the potential to address a broader range of neutrophilic dermatoses as well as other I&I diseases beyond the skin. We are excited to explore this potential in PG, where no approved treatments exist, as well as other I&I diseases.”

MC2 Therapeutics also continues to progress the development of its MC2-25 iso-cyanate scavenger for the treatment of Vulvar Lichen Sclerosus (“VLS”). The Company’s Phase 2a proof of concept trial for this indication remains on track, with topline results expected in Q4.

About MC2 Therapeutics

MC2 Therapeutics is a commercial stage biotech company focused on developing novel treatment paradigms for neutrophilic diseases.

Its pioneering approach in immunology is anchored in a deep understanding of skin biology, clinical expertise and cross-silo thinking.

Its pipeline includes two first-in-class drug candidates both in Phase 2 clinical development, with novel modes of action and blockbuster potential in multiple indications (“I&I pipeline in a product”):

  • MC2-32: an oral HSP90 inhibitor with unique tissue specific targeting and a new MOA that modulates multiple pro-inflammatory pathways and relevant immune responses.
  • MC2-25: an iso-cyanate scavenger addressing carbamylation of proteins and amino acids in the skin by iso-cyanate, a dissociation product of urea.

For additional information on MC2 Therapeutics Group, please visit www.mc2therapeutics.com

About MC2-32

MC2-32 (previously RGRN-305) is a new chemical entity small molecule, Heat Shock Protein 90 (HSP90) inhibitor, with a proven capability to clinically attenuate inflammation through a novel mode of action. MC2-32 modulates multiple inflammatory pathways relevant for HS, while the exceptional pharmacological properties of MC2-32 (specific tissue targeting) provide a remarkably favorable safety profile. MC2-32 has been tested successfully in a Phase 2a2a double-blinded, placebo-controlled, proof-of-concept trial in Hidradenitis Suppurativa and a small clinical trial in Plaque Psoriasis.

HSP90 is a group of chaperone molecules involved in several cellular processes, including cellular signaling and recent evidence has demonstrated that HSP90 inhibition has strong anti-inflammatory properties. MC2-32 selectively inhibits the two HSP90 isoforms, HSP90α and HSP90β and causes inhibition of several pro-inflammatory pathways involved in the pathogenesis of Hidradenitis Suppurativa.

MC2 Therapeutics acquired global (ex-greater China region) option rights to exclusively license MC2-32 (formerly RGRN-305) for all human indications from Regranion in September 2023.

About Hidradenitis Suppurativa (HS)

HS is an immune-mediated debilitating, life long, recurring, inflammatory skin disorder with a high, unmet medical need. It is characterized by chronic, painful nodules, abscesses, and suppurating sinus tracts that in the most severe form cause significant scarring. Commonly affected body locations include the armpits, below the breasts, the groin, the genitals, perineal and gluteal regions.

The pathogenesis of HS is complex and implicates activation of cells of both the innate and adaptive immune systems and involves several proinflammatory pathways. Broad immune modulation can therefore be a preferred strategy.        

About Pyoderma Gangrenosum (PG)

PG is one of a group of autoinflammatory disorders known as neutrophilic dermatoses. It presents as a rapidly enlarging, recurrent and very painful ulcer. The number of ulcers can vary from one to over a dozen and sometimes they coalesce. The classic morphologic clinical presentation of PG in its fully developed form is a deep ulcer with a purulent base and irregular, undermined blue/purple borders which extends centrifugally.
PG is often associated with other inflammatory or hematologic diseases.

MC2 Therapeutics A/S

Lonni Goltermann, +45 2018 1111 or log@mc2therapeutics.com

Media: ICR Consilium

Amber Fennell, +44 20 3709 5700, MC2@consilium-comms.com

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Subsea7 awarded a contract for the Belinda field in the UK North Sea25.5.2024 14:01:09 CEST | Press release

Luxembourg – 25 May 2024 - Subsea7 S.A. (Oslo Børs: SUBC, ADR: SUBCY) today announced the award of a sizeable1 contract by Serica Energy, for the Belinda field development south-east of the Triton FPSO. The Belinda field is operated by Serica Energy and located approximately 190 kilometres east of Aberdeen in the UK Central North Sea, with a water depth of 95 metres. The contract scope includes project management, engineering, procurement, construction and installation (EPCI) of a 5-kilometre 8” production pipeline with a 3” piggy-backed gas lift line and an electro-hydraulic controls (EHC) umbilical. Subsea7’s scope also includes associated subsea structures and tie-ins to the Triton Floating Production Storage & Offloading (FPSO) vessel operated by Dana Petroleum, via an existing production manifold near the Triton riser base and for controls at the Evelyn valve skid. Project management and engineering work will commence immediately in Aberdeen. The offshore activities are scheduled

Novartis atrasentan Phase III data show clinically meaningful proteinuria reduction further advancing company's IgA nephropathy (IgAN) portfolio25.5.2024 12:15:00 CEST | Press release

In the ALIGN study, atrasentan, in addition to supportive care with a renin-angiotensin system (RAS) inhibitor,demonstrated a statistically significant 36.1% proteinuria (protein in urine) reduction vs. placebo + supportive care at 36 weeks1 Endothelin A (ETA) receptor activation contributes to elevated proteinuria in IgAN2-5; atrasentan is a potent, selective ETA receptor antagonist with potential to reduce persistent proteinuria and preserve kidney function for a broad patient population1 IgAN is a heterogeneous, progressive, rare kidney disease with a need for effective, targeted therapies6,7; up to 30% of patients with persistent proteinuria (≥1 g/day) progress to kidney failure within 10 years8 Through its rare kidney disease portfolio, Novartis is committed to exploring a range of treatment options with different modes of action to slow IgAN progression Basel, May 25, 2024 – Novartis today presented results from a pre-specified interim analysis of the Phase III ALIGN study of atr

Novartis presents latest Phase III Fabhalta® (iptacopan) data in C3 glomerulopathy (C3G) showing clinically meaningful and statistically significant 35.1% proteinuria reduction vs. placebo25.5.2024 12:00:00 CEST | Press release

Secondary endpoint data for estimated glomerular filtration rate (eGFR) showed numerical improvement over 6 months vs. placebo1; additional 6-month open-label data to be presented at a future medical meeting2,3Fabhalta showed a favorable safety profile with no new safety signals1C3G, an ultra-rare kidney disease caused by alternative complement pathway overactivation, progresses to kidney failure in ∼50% of patients within 10 years4-7; currently there are no treatments approved for C3G7-9 Fabhalta, an oral Factor B inhibitor of the alternative complement pathway, selectively targets the underlying cause of C3G1; late-stage development program ongoing across several other rare diseases10-13 Basel, May 25, 2024 – Novartis today presented results from the 6-month, double-blind period of the Phase III APPEAR-C3G study of Fabhalta® (iptacopan) at the late-breaking clinical trials session of the European Renal Association (ERA) Congress1. Patients treated with Fabhalta in addition to support

Metasphere Labs Announces Development of Innovative Carbon Credit Protocol for Grid-Scale Batteries24.5.2024 22:05:00 CEST | Press release

VANCOUVER, British Columbia, May 24, 2024 (GLOBE NEWSWIRE) -- Metasphere Labs Inc. (formerly Looking Glass Labs Ltd., "Metasphere" or the "Company") (Cboe Canada: LABZ) (OTC: LABZF) (FRA: H1N) is excited to announce an innovative initiative aimed at accelerating the decarbonization of the electricity grid through the development of a pioneering carbon credit protocol for grid-scale batteries. Innovative Carbon Credit Protocol The Company is committed to leveraging advanced technology to address critical environmental challenges. The new carbon credit protocol will enable grid-scale batteries to monetize their environmental attributes by generating carbon credits for the carbon reductions achieved through optimized battery operations. This protocol is designed to incentivize the deployment and operation of grid-scale batteries, ensuring they play a pivotal role in the transition to a clean energy future. Submission to Pure Sky Carbon Credit Registry The Company intends to submit this pr

Nokia Corporation: Repurchase of own shares on 24.05.202424.5.2024 21:30:00 CEST | Press release

Nokia Corporation Stock Exchange Release 24 May 2024 at 22:30 EEST Nokia Corporation: Repurchase of own shares on 24.05.2024 Espoo, Finland – On 24 May 2024 Nokia Corporation (LEI: 549300A0JPRWG1KI7U06) has acquired its own shares (ISIN FI0009000681) as follows: Trading venue (MIC Code)Number of sharesWeighted average price / share, EUR*XHEL362,1533.55CEUX--BATE--AQEU--TQEX--Total362,1533.55 * Rounded to two decimals On 25 January 2024, Nokia announced that its Board of Directors is initiating a share buyback program to return up to EUR 600 million of cash to shareholders in tranches over a period of two years. The first phase of the share buyback program in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR), the Commission Delegated Regulation (EU) 2016/1052 and under the authorization granted by Nokia’s Annual General Meeting on 4 April 2023 started on 20 March 2024 and ends by 18 December 2024 with a maximum aggregate purchase price of EUR 300 million. Total cost of tra

HiddenA line styled icon from Orion Icon Library.Eye